JK0564

JK0564 is a small molecule pan-FGFR (Fibroblast Growth Factor Receptor) inhibitor developed by Tianjin Jikun Pharmaceutical Technology Co., Ltd. It is designed to target multiple isoforms of the FGFR family, specifically FGFR1, FGFR2, and FGFR3, which are frequently dysregulated in various malignancies through gene amplification, mutation, or translocation. By inhibiting these receptors, JK0564 blocks downstream signaling pathways such as MAPK/ERK and PI3K/AKT, which are critical for tumor cell proliferation, survival, and angiogenesis. The drug is currently being evaluated in Phase 1 clinical trials (e.g., CTR20232939) to assess its safety, tolerability, and pharmacokinetic profile in patients with advanced malignant solid tumors.